Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling

Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial

FDA Reconsiders Removal of Eli Lilly’s Tirzepatide from Shortage List, Boosting Compounding Pharmacies

FDA, Eli Lilly, Tirzepatide, GLP-1 drug, Shortage list, Compounding pharmacies, Weight loss medication, Type 2 diabetes treatment